Dr Rosa Nadal is a Medical Oncologist at the Cellular and Molecular Therapeutics Branch at the National Institutes of Health (NIH) in Bethesda, Maryland, USA. Dr Nadal graduated in Medicine and Surgery in 2000 at the Universidad Autònoma de Barcelona in Spain. She completed her Medical Oncology Fellowship at the Hospital de San Pau, a teaching hospital of the Universidad Autònoma de Barcelona. Dr Nadal completed her certification for clinical research and then studied tumour biology and development of biomarkers. Dr Nadal defended her PhD thesis at the Universitat Autònoma de Barcelona, graduating Cum Laude; she was recognised for outstanding academic achievement with the PhD Extraordinary Award. After completing her oncology training, she joined the faculty at the Solid Tumour Oncology Service of Hospital de Barcelona in 2007 and had an active clinical and translational research career, as well as a busy practice caring for patients with advanced genitourinary cancers, under the guidance of her clinical mentor, Dr Joaquim Bellmunt. From February 2012 to June 2015, she joined a genitourinary fellowship programme to gain additional training on the management of prostate cancer and biomarker development, specifically the clinical validation of the AR-V7, at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, Maryland, USA.
Dr Nadal joined the ACGME-accredited Hematology/Oncology Fellowship Program at the National Cancer Institute (NCI) in 2013. She worked closely with a multidisciplinary team to develop an early-phase trial of targeted therapies in combination with immunotherapies, with special focus on kidney and bladder cancer. The results of these studies led to larger trials in genitourinary malignancies, including CheckMate 9ER.
After completing her training at the NCI, she joined the Cellular and Molecular Therapeutics Branch at the NIH where she is currently conducting clinical trials to test new cellular immunotherapies for advanced kidney cancer patients. She also evaluates promising approaches to engineering NK cells to express chimeric antigen receptors to enhance their activity against genitourinary malignancies.
Dr Nadal has authored several original scientific and medical articles in high-impact, peer-reviewed journals.
Last update: October 2022